Literature DB >> 16804390

Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study).

Magne Henriksen1, Jørgen Jahnsen, Idar Lygren, Jostein Sauar, Øystein Kjellevold, Tom Schulz, Morten H Vatn, Bjørn Moum.   

Abstract

BACKGROUND: The majority of studies concerning the clinical course and prognosis in ulcerative colitis (UC) are old, retrospective in design, or hospital based. We aimed to identify clinical course and prognosis in a prospective, population-based follow-up study
MATERIALS AND METHODS: Patients diagnosed with inflammatory bowel disease (IBD) or possible IBD in southeastern Norway during the period 1990-1994 were followed prospectively for 5 years. The evaluation at 5 years included an interview, clinical examination, laboratory tests, and colonoscopy.
RESULTS: Of 843 patients diagnosed with IBD, 454 patients who had definite UC and for whom there were sufficient data for analysis were alive 5 years after inclusion in the study. The frequency of colectomy in this population was 7.5%. Forty-one percent of the patients were not taking any kind of medication for IBD at 5 years. Of the patients initially diagnosed with proctitis, 28% had progressed during the observation period, 10% to extensive colitis. The majority of the patients (57%) had no intestinal symptoms at 5 years, and only a minority (7%) had symptoms that interfered with everyday activities. Among the patients who underwent colonoscopy at the 5-year visit, symptoms were frequently reported in patients without macroscopic inflammation (44%). A relapse-free course was observed in 22% of the patients. A decrease in symptoms during the follow-up period was the most frequent course taken by the disease and was observed in 59% of the cases. The extent of disease was unrelated to symptoms at 5 years and also to relapse rate and course of disease during the 5-year period.
CONCLUSIONS: The disease course and prognosis of UC appears better than previously described in the literature. The frequency of surgery was low, and only a minority of the patients had symptoms that interfered with their everyday activities 5 years after diagnosis.

Entities:  

Mesh:

Year:  2006        PMID: 16804390     DOI: 10.1097/01.MIB.0000225339.91484.fc

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  62 in total

1.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

2.  Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties?

Authors:  Maria Elena Riccioni; Riccardo Urgesi; Rossella Cianci; Alessandra Bizzotto; Cristiano Spada; Guido Costamagna
Journal:  World J Gastrointest Endosc       Date:  2012-04-16

3.  Framework for assessing quality of care for inflammatory bowel disease in Sweden.

Authors:  Martin Rejler; Jörgen Tholstrup; Mattias Elg; Anna Spångéus; Boel Andersson Gäre
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

4.  Current trends in inflammatory bowel disease: the natural history.

Authors:  Ebbe Langholz
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 5.  Pain and inflammatory bowel disease.

Authors:  Klaus Bielefeldt; Brian Davis; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

6.  Crohn's disease: we are in it for the long haul. Interview by Paul C Adams.

Authors:  Remo Panaccione
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

Review 7.  Surgical treatment of ulcerative colitis in the biologic therapy era.

Authors:  Alberto Biondi; Marco Zoccali; Stefano Costa; Albert Troci; Ettore Contessini-Avesani; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

8.  Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.

Authors:  Sameer D Saini; Akbar K Waljee; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

9.  Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial.

Authors:  Mitsuro Chiba; Kunio Nakane; Tsuyotoshi Tsuji; Satoko Tsuda; Hajime Ishii; Hideo Ohno; Kenta Watanabe; Yu Obara; Masafumi Komatsu; Takeshi Sugawara
Journal:  Perm J       Date:  2019

10.  Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis.

Authors:  Richard Ahrens; Amanda Waddell; Luqman Seidu; Carine Blanchard; Rebecca Carey; Elizabeth Forbes; Maria Lampinen; Tara Wilson; Elizabeth Cohen; Keith Stringer; Edgar Ballard; Ariel Munitz; Huan Xu; Nancy Lee; James J Lee; Marc E Rothenberg; Lee Denson; Simon P Hogan
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.